Mylan has earned a strong reputation for expanding access high quality HIV/AIDS treatment through driving down the costs of antiretrovirals (ARV) for more than a decade. Beyond reducing costs, Mylan has introduced novel heat-stable generic formulations, more convenient packaging options, pediatric therapies and has built strong partnerships with other organizations that are taking action to fight HIV/AIDS around the world. More than 40% of the nearly 21 million HIV+ patients being treated today – and 60% of the world's HIV+ children – depend on one of our products.
India is home to the world's third largest population of people with HIV/AIDS, with approximately 2.1 million people living with the disease, of which fewer than 50% have access to treatment (UNAIDS). Recognizing the critical need to further increase access to HIV/AIDS care in India, Mylan launched its domestic business in 2012 with a comprehensive portfolio of ARVs, all of which are manufactured at Mylan's state-of-the-art facilities in India.